Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial
Lei Chen, Chaosu Hu, Xiao-Zhong Chen et al. · The Lancet Oncology · 2011
Cited by 558 works. doi:10.1016/s1470-2045(11)70320-5
Authors
- Lei Chen
- Chaosu Hu
- Xiao-Zhong Chen
- Guoqing Hu
- Zhi-Bin Cheng
- Yan Ping Sun
- Wei-Xiong Li
- Yuanyuan Chen
- Fang‐Yun Xie
- Shao-Bo Liang
- Yong Chen
- Ting-Ting Xu
- Bin Li
- Guo-Xian Long
- Si-Yang Wang
- Bao-Min Zheng
- Ying Qiang Guo
- Ying Hao Sun
- Yan‐Ping Mao
- Ling‐Long Tang
References
- Regression Models and Life-Tables
- Regression Models and Life-Tables
- Global cancer statistics
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
- Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
- Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin
- Sample Size Calculations in Clinical Research
- A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
- Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival